SEARCH

SEARCH BY CITATION

References

  • 1
    Tonini M. Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacol Res 1996; 33: 217 26.
  • 2
    Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631 51.
  • 3
    De Ponti F & Malagelada J-R. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther 1998; 80: 49 88.
  • 4
    Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG. Presynaptic, ganglionic, and gastrointestinal dopamine receptors in periphery. Pharmacol Rev 1985; 37: 165 216.
  • 5
    Costall B, Naylor RJ, Tuladhar BR. 5-HT4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum. Br J Pharmacol 1993; 110: 1572 8.
  • 6
    Tonini M, Spelta V, De Giorgio R, et al. A re-assessment of the pharmacodynamics of levosulpiride in the guinea pig gastrointestinal tract. Gastroenterology 1999; 116: A1093A1093(Abstract).
  • 7
    Tonini M, Galligan JJ, North RA. Effects of cisapride on cholinergic neurotransmission and propulsive motility in the guinea pig ileum. Gastroenterology 1989; 96: 1257 64.
  • 8
    Grider JR, Foxx-Orenstein AE, Jin J-G. 5-hydroxytryptramine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370 80.
  • 9
    Eglen RM, Wong EHF, Dumuis A, Bockaert J. Central 5-HT4 receptors. Trends Pharmacol Sci 1995; 16: 391 8.
  • 10
    Hegde SS & Eglen RM. Peripheral 5-HT4 receptors. FASEB J 1996; 10: 1398 407.
  • 11
    MacLean PG & Coupar IM. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors . Br J Pharmacol 1996; 117: 238 9.
  • 12
    Bunce KT, Elswood CJ, Ball MT. Investigation of the 5-hydroxytryptamine receptor mechanism mediating the short-circuit current response in rat colon. Br J Pharmacol 1991; 102: 811 6.
  • 13
    Borman RA & Burleigh DE. Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br J Pharmacol 1993; 110: 927 8.
  • 14
    Kaumann AJ & Sanders L. 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptor in human atrium: facilitation by chronic β–adrenoceptor blockade . Naunyn-Schmiedeberg’s Arch Pharmacol 1994; 349: 331 7.
  • 15
    Kaumann AJ, Lynham JA, Brown AM. Comparison of the densities of 5-HT4 receptors, β1- and β2-adrenoceptors in human atrium: functional implications . Naunyn-Schmiedeberg’s Arch Pharmacol 1996; 353: 592 5.
  • 16
    Lefebvre H, Gonzalez KN, Contesse V, Delarue C, Vaudry H, Kuhnl JM. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers . Endocr Res 1998; 24: 749 52.
  • 17
    Lefebvre H, Heron F, Contesse V, Delarue C, Vaudry H, Kuhn JM. Effect of the serotonin4 receptor agonist cisapride on plasma aldosterone levels in cirrhotic patients with secondary hyperaldosteronism. Eur J Clin Pharmacol 1998; 53: 479 80.
  • 18
    Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994; 113: 1 2.
  • 19
    Candura SM, Messori E, Franceschetti GP, et al. Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists. Br J Pharmacol 1996; 118: 1965 70.
  • 20
    Boyd IW & Rohan AP. Urinary disorders associated with cisapride. Med J Aust 1994; 160: 579 80.
  • 21
    Pillans PI & Wood MD. Cisapride increases micturition frequency. J Clin Gastroenterol 1994; 19: 336 46.
  • 22
    Tonini M & Candura SM. 5-HT4 receptor agonists and bladder disorders. Trends Pharmacol Sci 1996; 17: 314314.
  • 23
    Kaumann AJ. Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci 1994; 15: 451 5.
  • 24
    Ahmad SR & Wolfe SM. Cisapride and torsades de pointes. Lancet 1995; 345: 508508.
  • 25
    Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Inter Med 1995; 155: 765 8.
  • 26
    Wysowski DK & Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290 1.
  • 27
    Kii Y & Ito T. Effects of 5-HT4 receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29: 670 5.
  • 28
    Morgan TK & Sullivan ME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Progr Med Chem 1992; 29: 65 108.
  • 29
    Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential . J Pharmacol Exp Ther 1997; 282: 220 7.
  • 30
    Drici MD, Ebert SN, Wang WX, Rodriguez I, Liu XK, Whitfield BH, Woosley RL. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization and the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34: 82 8.
  • 31
    Crema F, Modini C, Croci T, Langlois M, De Ponti F. Intestinal prokinesia by two esters of 4-amino-5-chloro-2-methoxybenzoic acid: involvement of 5-HT4 receptors and dissociation from cardiac effects in vivo. J Pharmacol Exp Ther 1999; 288: 1045 52.
  • 32
    Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug- related lengthening of the QT interval. Circulation 1998; 97: 204 10.
  • 33
    Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedeberg’s Arch Pharmacol 1999; 359: 212 9.
  • 34
    Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10: 272 82.
  • 35
    Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534 8.
  • 36
    Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377 9.
  • 37
    Rampe D, Roy M-L, Dennis A, Brown AM. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28 32.
  • 38
    Montaz L, Varache N, Harry P, et al. Torsades de pointes during sultopride poisoning. J Toxicol Clin Exp 1992; 12: 481 96.
  • 39
    Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 1995; 14: 294 8.
  • 40
    Adamantidis MM, Kerram P, Dupuis BA. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 1994; 8: 391 407.
  • 41
    Malkoff MD, Ponzillo JJ, Myles GL, Gomez CR, Cruz-Flores S. Sinus arrest after administration of intravenous metoclopramide. Ann Pharmacother 1995; 29: 381 3.
  • 42
    Roden DM & George AL Jr. Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997; 273: H511 25.
  • 43
    Wager E, Tooley PJH, Pearce GL, Wilton LV, Mann RD. A comparison of two cohort studies evaluating the safety of cisapride: Prescription-event monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87 94.
  • 44
    Rampe D & Murawsky MK. Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin. Naunyn Schmiedeberg’s Arch Pharmacol 1997; 355: 743 50.
  • 45
    Wiseman LR & Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116 52.
  • 46
    Corinaldesi R, Stanghellini V, Tosetti C, et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429 32.
  • 47
    Pettignano R, Chambliss R, Darsey E, Heard M, Clark R. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med 1996; 24: 1268 71.
  • 48
    Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride- induced long QT interval. J Pediatr 1996; 128: 279 81.
  • 49
    Autret E, Jonville-Bera AP, Champel V. La toxicité cardiaque du cisapride (Prépulsid) mérite d’être prise en compte dans sa prescription, en particulier chez le prématuré. Arch Pédiatr 1997; 4: 507 8.
  • 50
    Lupoglazoff JM, Bedu A, Faure C, et al. Allongement de l’espace QT sous cisapride chez le nuveau-né et le nourrisson. Arch Pédiatr 1997; 4: 509 14.
  • 51
    Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI. Proarrhythmia associated with cisapride in children. Pediatrics 1998; 101: 1053 6.
  • 52
    Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. J Pediatr 1998; 133: 51 6.
  • 53
    Gray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998; 32: 648 51.
  • 54
    Bedford TA & Rowbotham DJ. Cisapride. Drug interactions of clinical significance. Drug Safety 1996; 15: 167 75.
  • 55
    Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Safety 1997; 17: 265 75.
  • 56
    Van Haarst AD, Van′t Klooster GA, Van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542 6.
  • 57
    Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106 11.
  • 58
    Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886 99.
  • 59
    Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995; 91: 3010 6.
  • 60
    Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28: 1836 48.
  • 61
    Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice–drug interactions. Br J Clin Pharmacol 1998; 46: 101 10.
  • 62
    Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33: 22 6.
  • 63
    Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Alim Pharmacol Ther 1998; 12: 823 37.
  • 64
    Gascon MP & Dayer P. Comparative effects of macrolide antibiotics on liver monoxygenases. Clin Pharmacol Ther 1991; 49: 158158.
  • 65
    Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746 51.
  • 66
    Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7: 148 56.
  • 67
    Von Rosensteil NA & Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105 22.
  • 68
    Itoh Z. Motilin and clinical application. Peptides 1997; 18: 593 608.